机译:MA26.09 Lazertinib,第三代EGFR-TKI,患者患有EGFR-TKI抗性NSCLC:I / II期研究的更新结果
Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei;
Center for Lung Cancer National Cancer Center;
Chungbuk National University Hospital Chungbuk National University College of Medicine;
Department of Internal Medicine Seoul National University Hospital;
Internal Medicine Kangbuk Smsung Hospital Sungkyunkwan University School of Medicine;
Division of Hemato-Oncology Gyeongsang National University Hospital Gyeongsang National;
Seoul National University Bundang Hospital Seoul National University College of Medicine;
Division of Medical Oncology Gachon University Gil Medical Center;
INJE University College of Medicine INJE University Haeundae Paik Hospital;
Division of Hematology and Oncology Ulsan University Hospital University of Ulsan College of;
Department of Internal Medicine Seoul Metropolitan Government Seoul National University Boramae;
Department of Internal Medicine Korea University Anam Hospital Korea University College of;
Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei;
Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Yonsei;
Division of Hematology-Oncology Department of Medicine Samsung Medical Center Sungkyunkwan;
Yuhan Research Institute Yuhan Corporation;
Yuhan Research Institute Yuhan Corporation;
Yuhan Research Institute Yuhan Corporation;
Yuhan Research Institute Yuhan Corporation;
Hematolog-Oncology Samsung Medical Center Sungkyunkwan University School of Medicine;
机译:MA26.09 Lazertinib,第三代EGFR-TKI,患者患有EGFR-TKI抗性NSCLC:I / II期研究的更新结果
机译:IRENE试验(NVALT-16)的原理和研究设计:评估具有激活EGFR突变且对EGFR-TKI用作一线或先前治疗有反应的晚期NSCLC患者的易瑞沙再挑战的II期试验
机译:MA 12.01 A EGFR-TKI在EGFR-TKI中的AFATINIB和Ruxolitinib中的组合的A相IB研究:更新的分析
机译:使用Sonablate〜(TM)系统以高强度聚焦超声微创治疗良性前列腺增生:在美国进行的III期临床研究的最新报告
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:多中心II期研究评估了未经化疗的单纯性NSCLC IB-IIIA期患者在手术前将多西紫杉醇顺铂和西妥昔单抗作为诱导方案的两个周期(INN06-研究)
机译:MA01.09伴随的SBRT和EGFR-TKI与OligometaTatic NSCLC的单独使用EGFR-TKI:多中心,随机期II研究